Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov:71:102951.
doi: 10.1016/j.amsu.2021.102951. Epub 2021 Oct 15.

Comparison of severity of immunized versus non-immunized COVID-19 patients admitted to ICU: A prospective observational study

Huda Mhawish  1 , Ahmed Mady  1   2 , Faisal Alaklobi  3 , Waleed Aletreby  1 , Tasmiya Asad  1 , Mohammed Alodat  1 , Abdulrahman Alharthy  1 , Basheer Abdulrahman  1 , Saleh Almahwi  1 , Ziad A Memish  4   5   6
Affiliations

Comparison of severity of immunized versus non-immunized COVID-19 patients admitted to ICU: A prospective observational study

Huda Mhawish et al. Ann Med Surg (Lond). 2021 Nov.

Abstract

Background: Vaccines against COVID-19 show high efficacy, yet, infection is still being detected among immunized patients, although with blunted severity. The purpose of this study was to assess the severity of COVID-19 infection among immunized versus non-immunized COVID-19 patients admitted to ICU.

Method: A prospective observational cohort study, including all COVID-19 patients admitted to intensive care unit between January 1st, 2021 and June 30th, 2021 were eligible for inclusion. A comparison of severity upon hospitalization of immunized versus non-immunized patients on a 7-level ordinal scale was conducted, using ordinal logistic regression.

Results: 592 patients were enrolled, 524 (88.5%) non-immunized, 63 (10.6%) partially immunized, and 5 (0.9%) fully immunized, partially and fully immunized patients were grouped together. Majority of immunized patients (86.7%) were symptomatic before 21 days of immunization. Non-immunized group had fewer patients in the lower severity categories, while more patients in the higher severity categories compared to immunized group. At least one dose of immunization was associated with reduction of odds of moving up severity scale (OR = 0.2 [95% CI: 0.15-0.4]; p < 0.001) in a well fitted ordinal logistic regression model. At least one dose of immunization was associated with lower adjusted odds of 30 day all-cause mortality (OR = 0.45 [95% CI: 0.23-0.89]; p = 0.02). Non-immunized group had higher mortality rate (43.9% versus 29.4% [95% CI: 1.5 to 25.8]; p = 0.02).

Conclusion: Most COVID-19 patients admitted to ICU were non-immunized, most of the partially immunized patients got infected before immunity could develop, and fully immunized patients were likely non-responders. At least one dose of immunization significantly decreases severity of the disease across all ordinal severity categories, and is significantly associated with lower 30 day all-cause mortality. Accordingly, immunization status may have to be considered when deciding on disposition of COVID-19 patients at the point of triage.

Keywords: COVID-19; ICU; Immunization; Severity.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflict of interests.

Figures

Fig. 1
Fig. 1
Percentage of enrolled patients by immunization status.
See this image and copyright information in PMC

References

    1. Asad T., Alharthy A., Abdullah Ba Lahmar Demographic, practice characteristics and risk factors of SARS-CoV-2 infection among ICU healthcare workers: a cross sectional and nested case control study. Int. J. Health Sci. Res. 2021;11(1):10–20.
    1. World health Organization website. https://covid19.who.int online at:, Accessed on.
    1. Amit S., Beni S.A., Biber A., Grinberg A., Leshem E., Regev-Yochay G. Postvaccination COVID-19 among healthcare workers, Israel. Emerg. Infect. Dis. 2021 Apr;27(4):1220–1222. - PMC - PubMed
    1. Polack F.P., Thomas S.J., Kitchin N. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. 2020;383:2603–2615. - PMC - PubMed
    1. Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99–111. - PMC - PubMed